Braveheart Bio seeks $319M in US IPO backed by a16z

Braveheart Bio Inc., a clinical-stage biopharmaceutical company barely eight months old, has filed for an initial public offering on the Nasdaq. The company is seeking to raise $319 million, backed by a roster of heavyweight life-science investors that includes Andreessen Horowitz’s Bio + Health division. The filing, submitted to the SEC on July 15, 2026, under the proposed ticker symbol “BRVE,” marks one of the more aggressive IPO timelines in recent biotech history. Founded in November 2025 with a $185 million Series A, Braveheart is now racing toward public markets with clinical data in hand and Phase 3 trials on the horizon. A crypto VC firm’s non-crypto bet The other investors lining up behind Braveheart are pure-play life sciences players: Forbion, OrbiMed, and Enavate Sciences. Notably, Braveheart’s IPO filing does not reference any crypto assets or blockchain technologies, emphasizing its commitment to advancing traditional small-molecule therapeutics. The drug and the data Braveheart’s lead asset is BHB-1893, an oral cardiac myosin inhibitor designed to treat hypertrophic cardiomyopathy, or HCM. In English: it’s a pill that aims to help patients whose heart muscle is abnor...